Practice and Implication of New Medicines Included in the WHO Essential Medicine List
- VernacularTitle:新药纳入世界卫生组织基本药物目录的实践与启示
- Author:
Xuedan YUAN
1
;
Rui GENG
;
Jixuan WANG
Author Information
1. 上海市卫生和健康发展研究中心(上海市医学科学技术情报研究所) 上海 200040
- Publication Type:Journal Article
- Keywords:
new medicine;
WHO essential medicines list;
National Essential Medicines List;
rights of life and health;
cancer medicine
- From:
Chinese Health Economics
2025;44(9):104-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective:As medical demands rose rapidly and innovative pharmaceuticals continuously launched onto the market,the National Essential Medicines List(NEML)confronted a novel challenge whether or not to include new medicines.The practice of WHO including new medicines in the WHO Essential Medicines List(WHO EML)was analyzed to provide references for the adjustment of NEML.Methods:Based on the theory of the right to life and health,it explored the theoretical basis of WHO incorporating new medicines into WHO EML.The cancer medicines were taken as the examples to investigate evaluation criteria.Results:For the selection of new medicines,WHO refined multi-dimensional evaluation criteria and took targeted measures to improve selection process and management system.Conclusion:When China attempted to include new drugs in the NEML,it was necessary to adjust selection concept,optimize selection process,improve NEML structure and content,improve selection criteria and strengthen the construction of selection and management guarantee system.
